{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T13:05:51Z","timestamp":1774011951977,"version":"3.50.1"},"reference-count":26,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2005,8,1]],"date-time":"2005-08-01T00:00:00Z","timestamp":1122854400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2005,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Carbohydrate Antigen 125 (CA 125), a marker for ovarian cancer has been reported to increase in relation to the severity of heart failure.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate the serum levels of CA 125 and other tumour markers, in patients with chronic heart failure.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Blood levels of CA 125 and other tumour markers were determined in 44 heart failure patients (16 males and 28 females; age 66.3\u00b16.5 years) before and after optimal medical treatment. Levels were also evaluated in 30 healthy volunteers (11 males and 19 females; age 65.7\u00b19.8 years). The results in the heart failure patients were grouped according to clinical status (New York Heart Association Class). The mean duration of follow-up was 3\u00b11.5 months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The mean serum level of CA 125 was 81.9\u00b191 in the patient group and 7.5\u00b14.8 in control group (p&amp;lt;0.001). The mean CA 19-9 level in the patient group (16.8\u00b116.6) was significantly higher than in the control group (4.5\u00b12.6) (p&amp;lt;0.001). CA 125 levels increased as the New York Heart Association (NYHA) functional class increased (Class I\/II: 17.7\u00b122.4 U\/ml; Class III: 99.6\u00b192.1 U\/ml; Class IV 136.4\u00b1102.8 U\/ml; p&amp;lt;0.05). There were no significant differences in serum CA 125 and other tumour marker levels before and after optimisation of treatment. Significantly higher serum CA 125 levels were found in patients with pericardial effusion (p=0.002) when compared to patients without pericardial effusion.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Among the tumour markers evaluated, only CA 125 seems to be specifically related to the presence and severity of heart failure and also the presence of pericardial fluid. Therefore, measurements of CA 125 serum levels might be proposed for the serial assessment of heart failure. Whether CA 125 has a specific biological role in heart failure requires further investigation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1016\/j.ejheart.2004.12.008","type":"journal-article","created":{"date-parts":[[2005,5,25]],"date-time":"2005-05-25T08:41:42Z","timestamp":1117010502000},"page":"840-843","source":"Crossref","is-referenced-by-count":49,"title":["Tumour Marker Levels in Patients with Chronic Heart Failure"],"prefix":"10.1093","volume":"7","author":[{"given":"Ercan","family":"Varol","sequence":"first","affiliation":[{"name":"Department of Cardiology, Isparta State Hospital , Anadolu Mah. ESO (memur) Evleri C Blok No:5, 32200, Isparta ,","place":["Turkey"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehmet","family":"Ozaydin","sequence":"additional","affiliation":[{"name":"Department of Cardiology, S\u00fcleyman Demirel University , Isparta ,","place":["Turkey"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdullah","family":"Dogan","sequence":"additional","affiliation":[{"name":"Department of Cardiology, S\u00fcleyman Demirel University , Isparta ,","place":["Turkey"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feridun","family":"Kosar","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Inon\u00fc University , Malatya ,","place":["Turkey"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2005,8,7]]},"reference":[{"key":"2026020203561134400_ejhf2004-12-008-bib-0001","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1093\/clinchem\/39.11.2431","article-title":"Serum tumor markers for patient monitoring: a case-oriented approach illustrated with carcinoembryonic antigen","volume":"39","author":"Fritsche","year":"1993","journal-title":"Clin. Chem."},{"key":"2026020203561134400_ejhf2004-12-008-bib-0002","doi-asserted-by":"crossref","first-page":"623","DOI":"10.7326\/0003-4819-115-8-623","article-title":"Clinical applications of serum tumor markers","volume":"115","author":"Bates","year":"1991","journal-title":"Ann. Intern. Med."},{"key":"2026020203561134400_ejhf2004-12-008-bib-0003","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/0028-2243(93)90135-Y","article-title":"CA 125 in gynecological pathology: a review","volume":"49","author":"Kenemans","year":"1993","journal-title":"Eur. J. Obstet. Gynecol. Reprod. Biol."},{"key":"2026020203561134400_ejhf2004-12-008-bib-0004","first-page":"36","article-title":"CA 125 in ovarian cancer","volume":"40","author":"Vander Burg","year":"1992","journal-title":"Neth. J. Med."},{"key":"2026020203561134400_ejhf2004-12-008-bib-0005","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/0028-2243(93)90056-I","article-title":"Highly elevated serum CA 125 levels in a patient with cardiac failure","volume":"48","author":"Hopman","year":"1993","journal-title":"Eur. J. Obstet. Gynecol. Reprod. Biol."},{"key":"2026020203561134400_ejhf2004-12-008-bib-0006","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/S0002-8703(99)70360-1","article-title":"CA 125 and its relation to cardiac function","volume":"137","author":"N\u00e4gele","year":"1999","journal-title":"Am. Heart J."},{"key":"2026020203561134400_ejhf2004-12-008-bib-0007","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1016\/S0735-1097(03)00311-5","article-title":"Serum levels of carbohydrate Antigen 125 in patients with chronic heart failure. Relation to clinical severity, hemodynamic and Doppler echocardiographic abnormalities and short-term prognosis","volume":"41","author":"A\u2019loia","year":"2003","journal-title":"J. Am. Coll. Cardiol."},{"key":"2026020203561134400_ejhf2004-12-008-bib-0008","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1159\/000074425","article-title":"Serum CA 125 levels in patients with chronic heart failure and accompanying pleural fluid","volume":"24","author":"Turk","year":"2003","journal-title":"Tumor Biol."},{"issue":"4A","key":"2026020203561134400_ejhf2004-12-008-bib-0009","first-page":"2531","article-title":"Fluctuations of tumor markers in heart failure patients pre and post heart transplantation","volume":"19","author":"Nagele","year":"1999","journal-title":"Anticancer Res."},{"key":"2026020203561134400_ejhf2004-12-008-bib-0010","first-page":"223","article-title":"CA 125 for the monitoring of ovarian carcinoma during primary therapy","volume":"69","author":"Lavin","year":"1987","journal-title":"Obstet. Gynecol."},{"key":"2026020203561134400_ejhf2004-12-008-bib-0011","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1006\/gyno.2002.6603","article-title":"The significance of serum CA 125 elevation malignant and nonmalignant diseases","volume":"85","author":"Sjovall","year":"2002","journal-title":"Gynecol. Oncol."},{"key":"2026020203561134400_ejhf2004-12-008-bib-0012","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1136\/ijgc-00009577-200209000-00005","article-title":"The effect of ascites, mass volume, and peritoneal carcinomatosis on serum CA 125 levels in patients with ovarian carcinoma","volume":"12","author":"Saygili","year":"2002","journal-title":"Int. J. Gynecol. Cancer"},{"key":"2026020203561134400_ejhf2004-12-008-bib-0013","first-page":"1201","article-title":"Elevated serum CA 125 levels in patients with nephrotic syndrome induced ascites","volume":"20","author":"Sevin\u00e7","year":"2000","journal-title":"Anticancer Res."},{"key":"2026020203561134400_ejhf2004-12-008-bib-0014","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1006\/gyno.1999.5670","article-title":"Elevated serum CA 125 levels: hepatitis or ascites=","volume":"76","author":"Sevinc","year":"2000","journal-title":"Gynecol. Oncol."},{"key":"2026020203561134400_ejhf2004-12-008-bib-0015","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1006\/gyno.1999.5670","article-title":"Elevated serum CA 125 levels in hemodialysis patients with peritoneal, pleural or pericardial fluids","volume":"76","author":"Sevinc","year":"2000","journal-title":"Gynecol. Oncol."},{"key":"2026020203561134400_ejhf2004-12-008-bib-0016","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1093\/humrep\/15.6.1261","article-title":"CA 125 production by peritoneum: in-vitro and in-vivo studies","volume":"15","author":"Epiney","year":"2000","journal-title":"Hum. Reprod."},{"key":"2026020203561134400_ejhf2004-12-008-bib-0017","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/978-1-4899-2052-2_25","volume-title":"Use of biomarkers in assessing health and environmental impacts of chemical pollutants","author":"Gullu","year":"1993"},{"key":"2026020203561134400_ejhf2004-12-008-bib-0018","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1253\/jcj.57.489","article-title":"Usefulness of serum CA 125 measurement for monitoring pericardial effusion","volume":"57","author":"Seo","year":"1993","journal-title":"Jpn. Circ. J."},{"key":"2026020203561134400_ejhf2004-12-008-bib-0019","first-page":"221","article-title":"An autopsy case of malignant lymphoma with a high serum CA 125 level occurring only in the brain and the pericardium","volume":"27","author":"Watanabe","year":"1996","journal-title":"J. Med."},{"key":"2026020203561134400_ejhf2004-12-008-bib-0020","first-page":"1712","article-title":"Chronic constrictive pericarditis responsible for an increase of CA 125 levels, two cases (in French)","volume":"19","author":"Cacoub","year":"1990","journal-title":"Presse M\u00e9d."},{"key":"2026020203561134400_ejhf2004-12-008-bib-0021","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/0277-5379(88)90308-2","article-title":"The ovarian cancer associated antigen CA 125 in patients with pleural effusions","volume":"24","author":"Lindgren","year":"1988","journal-title":"Eur. J. Cancer Clin. Oncol."},{"key":"2026020203561134400_ejhf2004-12-008-bib-0022","first-page":"3129","article-title":"Modulation of CA 125 release by inflammatory cytokines in human peritoneal mesothelial and ovarian cancer cells","volume":"17","author":"Zeimet","year":"1997","journal-title":"Anticancer Res."},{"key":"2026020203561134400_ejhf2004-12-008-bib-0023","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1046\/j.1365-2141.1997.2383054.x","article-title":"High serum level of CA 125 and interleukin-6 in a patient with Ki-1 lymphoma","volume":"98","author":"Kubonishi","year":"1997","journal-title":"Br. J. Haematol."},{"key":"2026020203561134400_ejhf2004-12-008-bib-0024","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1016\/S0002-9149(96)00063-X","article-title":"Circulating interleukin-6 in severe heart failure","volume":"79","author":"Mac Gowen","year":"1997","journal-title":"Am. J. Cardiol."},{"key":"2026020203561134400_ejhf2004-12-008-bib-0025","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1161\/01.CIR.92.6.1479","article-title":"Tumor necrosis factor soluble receptors in patients with various degree of congestive heart failure","volume":"92","author":"Ferrari","year":"1995","journal-title":"Circulation"},{"issue":"5","key":"2026020203561134400_ejhf2004-12-008-bib-0026","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1177\/000331979905000506","article-title":"Circulating cytokines and complements in chronic heart failure","volume":"50","author":"Ko\u015far","year":"1999","journal-title":"Angiology"}],"container-title":["European Journal of Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1016%2Fj.ejheart.2004.12.008","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1016%2Fj.ejheart.2004.12.008","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/7\/5\/840\/66637879\/eurjhf_7_5_840.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/7\/5\/840\/66637879\/eurjhf_7_5_840.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T08:56:23Z","timestamp":1770022583000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjhf\/article\/7\/5\/840\/8445105"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,8,1]]},"references-count":26,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2005,8,7]]},"published-print":{"date-parts":[[2005,8,1]]}},"URL":"https:\/\/doi.org\/10.1016\/j.ejheart.2004.12.008","relation":{},"ISSN":["1388-9842","1879-0844"],"issn-type":[{"value":"1388-9842","type":"print"},{"value":"1879-0844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2005,8]]},"published":{"date-parts":[[2005,8,1]]}}}